Gilead Sciences (NASDAQ:GILD) Price Target Raised to $165.00

Gilead Sciences (NASDAQ:GILD) had its price target hoisted by research analysts at Wells Fargo & Company from $150.00 to $165.00 in a report issued on Wednesday,MarketScreener reports. The firm currently has an “overweight” rating on the biopharmaceutical company’s stock. Wells Fargo & Company‘s target price indicates a potential upside of 7.47% from the company’s previous close.

A number of other brokerages have also recently weighed in on GILD. JPMorgan Chase & Co. upped their price objective on Gilead Sciences from $150.00 to $160.00 and gave the stock an “overweight” rating in a research note on Wednesday. The Goldman Sachs Group increased their price objective on Gilead Sciences from $110.00 to $115.00 and gave the stock a “neutral” rating in a research report on Thursday, January 8th. Rothschild & Co Redburn increased their price target on shares of Gilead Sciences from $153.00 to $159.00 and gave the stock a “buy” rating in a research report on Tuesday, January 20th. Weiss Ratings reiterated a “buy (b)” rating on shares of Gilead Sciences in a research note on Thursday, January 22nd. Finally, Truist Financial increased their price objective on shares of Gilead Sciences from $140.00 to $145.00 and gave the company a “buy” rating in a research report on Tuesday, January 27th. Twenty-five analysts have rated the stock with a Buy rating and three have given a Hold rating to the company. According to data from MarketBeat, the stock presently has an average rating of “Moderate Buy” and a consensus price target of $141.85.

Gilead Sciences Stock Performance

Shares of Gilead Sciences stock opened at $153.54 on Wednesday. The firm’s 50-day moving average is $128.39 and its 200 day moving average is $121.53. The company has a debt-to-equity ratio of 1.03, a current ratio of 1.45 and a quick ratio of 1.31. Gilead Sciences has a 1 year low of $93.37 and a 1 year high of $153.13. The stock has a market cap of $190.49 billion, a price-to-earnings ratio of 23.65, a PEG ratio of 0.80 and a beta of 0.36.

Gilead Sciences (NASDAQ:GILD) last released its quarterly earnings results on Tuesday, February 10th. The biopharmaceutical company reported $1.86 earnings per share for the quarter, beating the consensus estimate of $1.83 by $0.03. The firm had revenue of $7.93 billion for the quarter, compared to analysts’ expectations of $7.68 billion. Gilead Sciences had a return on equity of 51.86% and a net margin of 27.88%.The company’s revenue was up 4.7% compared to the same quarter last year. During the same period in the prior year, the firm earned $1.90 EPS. Gilead Sciences has set its FY 2026 guidance at 8.450-8.850 EPS. Sell-side analysts anticipate that Gilead Sciences will post 7.95 EPS for the current fiscal year.

Insiders Place Their Bets

In related news, Director Jeffrey Bluestone sold 5,000 shares of the stock in a transaction dated Tuesday, January 20th. The stock was sold at an average price of $123.50, for a total value of $617,500.00. Following the completion of the transaction, the director owned 8,920 shares of the company’s stock, valued at approximately $1,101,620. This represents a 35.92% decrease in their ownership of the stock. The sale was disclosed in a document filed with the SEC, which is accessible through this link. Also, CEO Daniel Patrick O’day sold 115,640 shares of Gilead Sciences stock in a transaction dated Thursday, February 5th. The stock was sold at an average price of $150.00, for a total value of $17,346,000.00. Following the completion of the transaction, the chief executive officer owned 613,912 shares of the company’s stock, valued at $92,086,800. This trade represents a 15.85% decrease in their ownership of the stock. The disclosure for this sale is available in the SEC filing. In the last quarter, insiders have sold 319,391 shares of company stock valued at $44,141,101. Company insiders own 0.27% of the company’s stock.

Institutional Inflows and Outflows

Several large investors have recently added to or reduced their stakes in GILD. Paulson Wealth Management Inc. lifted its stake in shares of Gilead Sciences by 1.8% in the 4th quarter. Paulson Wealth Management Inc. now owns 3,887 shares of the biopharmaceutical company’s stock valued at $477,000 after purchasing an additional 67 shares during the last quarter. Essex Financial Services Inc. raised its position in Gilead Sciences by 0.9% in the fourth quarter. Essex Financial Services Inc. now owns 7,724 shares of the biopharmaceutical company’s stock worth $948,000 after purchasing an additional 71 shares in the last quarter. Alpha Cubed Investments LLC lifted its holdings in shares of Gilead Sciences by 1.1% during the fourth quarter. Alpha Cubed Investments LLC now owns 6,619 shares of the biopharmaceutical company’s stock valued at $812,000 after acquiring an additional 75 shares during the period. Personal CFO Solutions LLC lifted its position in shares of Gilead Sciences by 1.7% during the fourth quarter. Personal CFO Solutions LLC now owns 4,572 shares of the biopharmaceutical company’s stock worth $561,000 after purchasing an additional 76 shares in the last quarter. Finally, Moss Adams Wealth Advisors LLC increased its position in Gilead Sciences by 1.7% in the fourth quarter. Moss Adams Wealth Advisors LLC now owns 4,446 shares of the biopharmaceutical company’s stock worth $546,000 after purchasing an additional 76 shares during the period. Institutional investors and hedge funds own 83.67% of the company’s stock.

Gilead Sciences News Roundup

Here are the key news stories impacting Gilead Sciences this week:

• Positive Sentiment: Needham reiterated a Buy and raised its price target to $170, reflecting confidence in HIV momentum and margin expansion. Analyst Note
• Positive Sentiment: Scotiabank raised its price target from $140 to $177 and kept a “sector outperform” stance — a sizable upside vs. the current price that supports further upside expectations. Benzinga
• Positive Sentiment: Cantor Fitzgerald bumped its target to $155 and moved to Overweight, adding institutional buying interest. Benzinga
• Positive Sentiment: Gilead beat Q4 estimates — $1.86 EPS vs. $1.83 consensus and revenue roughly $7.9B — signaling continued strength in its core HIV and liver-disease franchises. Reuters
• Positive Sentiment: Board approved a 3.8% quarterly dividend increase to $0.82 per share (payable March 30), supporting income investors and the yield profile. Business Wire
• Neutral Sentiment: Q4 earnings materials and the conference call transcript provide detail on product trends (Yeztugo launch, HIV portfolio). Useful for modeling revenue cadence but not immediate market-moving by itself. Yahoo Finance
• Negative Sentiment: Gilead’s FY‑2026 guidance came in light: EPS guidance $8.45–$8.85 (consensus ~$8.69) and revenue guidance $29.6–$30.0B vs. ~$30.1B consensus — investors focused on the downside of the outlook. Benzinga
• Negative Sentiment: Because guidance missed some street expectations, shares dipped in after‑hours/extended trading — the immediate market reaction is driven more by forward guidance than yesterday’s beat. MSN

About Gilead Sciences

Gilead Sciences, Inc, founded in 1987 and headquartered in Foster City, California, is a biopharmaceutical company focused on the discovery, development and commercialization of medicines in areas of high unmet medical need. The company initially built its reputation in antiviral therapies and has since expanded into oncology, cell therapy and inflammatory diseases. Gilead operates a global research and commercial organization, conducting clinical development and selling medicines in markets around the world.

Gilead’s product portfolio is anchored by antiviral therapies for HIV and viral hepatitis.